MedTrace Logo

Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)

NCT01329471 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2011-04-06

No results posted yet for this study

Summary

The purpose of this study is to elucidate the role of RUNX1 in Acute Myeloid Leukemia (AML), in particular, the transcriptional regulation of genes by mutated forms of this protein. This research will study the effect of mutations found in AML patients

Conditions

Sponsors & Collaborators

  • Weizmann Institute of Science

    collaborator OTHER

  • Hillel Yaffe Medical Center

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-04-30
Completion
2013-04-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01329471 on ClinicalTrials.gov